36.6 F
New York
Wednesday, January 27, 2021

Eli Lilly [NYSE: LLY] Seeks FDA Emergency Use Authorization For COVID-19 Antibody Therapy

Must read

Humanigen [NASDAQ: HGEN] Announces Expansion Of Manufacturing Agreement With Ajinomoto Bio-Pharma

Humanigen Inc revealed that the company has extended the manufacturing agreement with  Ajinomoto BioPharma to support the fill-finish of Lenzilumab. The Lenzilumab is...

Synchrony [NYSE: SYF] Announced To Purchase Allegro Credit

Synchrony Financials revealed that the company entered into a definitive contract to Purchase Allegro Credit. Allegro Credit's customer base and merchant network will...

Vericel Corp [NASDAQ: VCEL] Names Joe Mara As The New CFO

Vericel Corporation revealed that the company has named Joe Mara as the CFO of the company. He has over more than 20 years...

A Paychex [NASDAQ: PAYX] Subsidiary Announces Strategic Collaboration With Zoho Books

SurePayroll, a subsidiary of Paychex company revealed that the company has formed a collaboration with Zoho books. SurePAyroll is a provider of small...

Eli Lilly and Company [NYSE: LLY] disclosed Wednesday that it has submitted an application to the FDA for the emergency use authorization of COVID-19 monoclonal antibody treatment.

Emergency Use Authorization (EUA) is not a complete approval but it is a sort of regulatory authorization to accelerate the process of bringing new therapies to the market.

Eli Lilly has earlier disclosed that the self-governing candidate, LY-CoV555, has shown a promising result in the clinical trial. The drug candidate has reduced the rate of hospitalization.

Vaccine candidate has also shown the encouraging results as it reduced the viral infection in some mild to moderately ill COVID-19 patients.

Eli Lilly and Company [NYSE: LLY] shares traded up 2.97% during the trading session of Wednesday. It has a closing price of $148.41. The drug manufacturing company had a trading volume of 171.36K as compared to the average volume of 3.08 Million.

This company stock has changed between the 52-weeks low range of $101.36 and a high range of $170.75. It has moved up 46.42% from its 52-weeks low and moved down -13.08% from its 52-weeks high.

Looking at its liquidity, it has a current ratio of 1.20. This company market capitaliztaion has remained high, hitting $136.98 billion at the time of writing.

Eli Lilly revealed that it has the capability to produce the one million doses of monotherapy in the Q4. The company has shared the Phase II clinical results of LY-CoV555 and LY-CoV016, another antibody-based therapy, in 268 patients. 

It has reported encouraging results as the candidates are proven to be useful in reducing the viral infection in patients.

More articles

Latest article

MGP Ingredients [NASDAQ: MGPI] Announced To Acquire Luxco and Its Affiliate Companies

MGP Ingredients  revealed a definitive contract to purchase Luxco, Inc and its affiliated companies. Luxco is an alcohol beverage company with more than 60...

Conformis [NASDAQ: CFMS] Entered A Non-Exclusive agreement with SITES Medical

Conformis Inc revealed that the company inked a development and supply contract with sites medical. Both of the companies will work together to...

Colliers International [NASDAQ: CIGI] Announces Executive Leadership Changes For Australian Business

Colliers International  reported that the company has named Malcom Tyson as the new Chief Executive Officer. He is appointed as the CEO so...

Korn Ferry [NYSE: KFY] Announces Expansion Of Its Footprint In Russian Market

Korn Fery revealed that the company is expanding its footprint in Russia. Moreover, it is adding a high expertise team of executive search...

Haemonetics [NYSE: HAE] To Purchase Cardiva For An Upfront Payment Of $475M

Haemonetics Corporation revealed that the company has inked a definitive contract to purchase Cardiva Medical Inc. Under the contract, Haemontics will pay an...

Philips [NYSE: PHG] To Purchase Capsule Technologies For Cash Consideration Of USD 635M

Koninklijke Philip revealed that the company has inked a contract to purchase Capsule technologies. The company will pay a cash price of $636...

Thermo Fisher Scientific [NYSE: TMO] To Purchase Mesa Biotech For Approx. $450M In Cash

Thermo fisher scientific inc revealed that the company has signed a definitive contract to purchase Mesa Biotech. Thermo will pay a value price...

Shutterstock [NYSE: SSTK] To Extend Its Agreement With EPA

Shutterstock reported that the company renewed its exclusive contract with the European Pressphoto Agency. The extended contract is to distribute the visual content...